Another study explains that GM-CSF signaling is indispensable for Nf1−/− induced MPN development, indicating therapeutic benefit by targeting GM-CSF signaling in NF1 mutated myeloid disorders [159]. This evidence concerns the gene CSF2 and myeloproliferative neoplasm.